Treatment Algorithm for Stage IIB and Beyond Melanoma

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

The FDA indicated that data from the phase 1/2 IGNYTE trial were not adequate to provide evidence of effectiveness.

The B7-H3–low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.